Health
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19 – GlobeNewswire
Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
CALGARY, Alberta, March 03, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) and QIMR Berghofer Medical Research Institute (QIMR Berghofer), one of Australias most successful medical research institutes, announced today the publishing of a new article providing evidence of apabetalones potential benefit on SARS-CoV-2 (COVID-19). The article, titled: Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical),…
-
General17 hours agoMore buses without dedicated lanes likely after Gold Coast light rail plan scrapped
-
Business23 hours agoBuy this monthly high-yield ETF instead
-
Business21 hours agoThis artificial intelligence (AI) stock could be the Nvidia of quantum computing
-
Business21 hours agoTesla just offered Elon Musk $1 trillion. Here’s what it could mean for the company.